| TIVDAQ Seagen Inc.
2149847 25 Oct 2021 | on 31 Dec 1969 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for use in humans, namely, chemotherapeutics and biopharmaceuticals for the treatment of nervous system diseases, for the regulation of the immune system and for treatment of auto-immune diseases, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of cancer, and inflammatory disorders, for use in dermatology namely dermatitis, skin pigmentation diseases, acne, eczema, psoriasis, oncology, hematology, ophthalmology, gastroenterological disorders, and tissue and organ transplantology; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; pharmaceutical preparations for the treatment of cancer, autoimmune diseases, and inflammatory disorders; pharmaceutical preparations for use in dermatology namely dermatitis, skin pigmentation diseases, acne, eczema, psoriasis, oncology, hematology, ophthalmology, gastroenterological disorders, and tissue and organ transplantology Class 042 Class 042 Computer & Software Services & Scientific Services Biotechnology research, namely, research and development of pharmaceutical preparations for use in humans; research and development of pharmaceutical preparations for the diagnosis, prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; research and development of pharmaceutical preparations for the diagnosis, prevention and treatment of cancer, autoimmune diseases, inflammatory disorders, gastroenterological disorders and for use in dermatology, oncology, hematology, ophthalmology, and tissue and organ transplantation | |